scholarly journals PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies

2016 ◽  
Vol 19 (Suppl_1) ◽  
pp. 55-55
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Meta Analysis ◽  
Adjunctive Treatment ◽  
Efficacy And Safety ◽  
Major Depressive

scholarly journals Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis

2015 ◽  
Vol 05 (10) ◽  
pp. 430-439
Author(s):  
Masoud Behzadifar ◽  
Abouzar Keshavarzi ◽  
Abed Tofighian ◽  
Mohammad Rastian ◽  
Mohammad Zobidi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Major Depressive

scholarly journals Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis

2019 ◽  
Vol 22 (11) ◽  
pp. 698-709
Author(s):  
Taro Kishi ◽  
Kenji Sakuma ◽  
Ikuo Nomura ◽  
Yuki Matsuda ◽  
Kazuo Mishima ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Scale Score ◽  
Response Rate ◽  
Meta Analysis ◽  
Weight Increase ◽  
Adjunctive Treatment ◽  
Number Needed To Treat ◽  
Major Depressive ◽  
Severity Scores

Abstract Background This systematic review and meta-analysis included double-blind, randomized, placebo-controlled trials of brexpiprazole adjunctive treatment (0.5–3 mg/d) for major depressive disorder where antidepressant treatment had failed. Methods The outcomes were the response rate (primary), remission rate (secondary), Montgomery Åsberg Depression Rating Scale score (secondary), Sheehan Disability Scale scores (secondary), Clinical Global Impression–Improvement/Severity scores, discontinuation rate, and individual adverse events. A subgroup meta-analysis of the data at week 6 compared outcomes by dose >2 mg/d or ≤2 mg/d (2 mg/d is the recommended dose). Results We identified 9 studies (n = 3391). Compared with placebo, brexpiprazole (any dose) was superior for response rate (risk ratio [RR] = 0.93, 95% confidence interval [95% CI] = 0.89−0.97, number needed to treat = 17), remission rate (RR = 0.95, 95% CI = 0.93−0.98, number needed to treat = 25), Montgomery Åsberg Depression Rating Scale score (standardized mean difference = −0.20, 95% CI = −0.29, −0.11), Sheehan Disability Scale score (standardized mean difference = −0.12, 95% CI = −0.21, −0.04), and Clinical Global Impression–Improvement/Severity scores but was associated with a higher discontinuation rate, akathisia, insomnia, restlessness, somnolence, and weight increase. Doses >2 mg/d had a significantly higher RR for response rate than ≤2 mg/d (0.96 vs 0.89); moreover, compared with placebo, doses >2 mg/d were associated with higher incidences of akathisia (RR = 4.58) and somnolence (RR = 7.56) as well as were marginally associated with a higher incidence of weight increase (RR = 3.14, P = .06). Compared with placebo, doses ≤2 mg/d were associated with higher incidences of akathisia (RR = 2.28) and weight increase (RR = 4.50). Conclusions Brexpiprazole adjunctive treatment is effective for major depressive disorder when antidepressant treatment fails. At 6 weeks, doses ≤2 mg/d presented a better risk/benefit balance than >2 mg/d.

Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety

2018 ◽  
Vol 32 (4) ◽  
pp. 385-396 ◽  
Author(s):  
Bruno Romeo ◽  
Lisa Blecha ◽  
Katia Locatelli ◽  
Amine Benyamina ◽  
Catherine Martelli
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Mood Disorder ◽  
Dopamine Agonists ◽  
Low Dose ◽  
Meta Analysis ◽  
High Dose ◽  
Efficacy And Safety ◽  
Major Depressive ◽  
Remission Rates

The objective of this meta-analysis is to assess the efficacy and safety of partial and complete dopamine agonists in the treatment of acute mood disorder episodes. Randomized, double-blind and placebo-controlled trials of dopamine agonists in the treatment of acute mood disorder episodes were identified in the MEDLINE and PsycINFO databases and included in the meta-analysis. In monotherapy of mania, improved remission rates were found for cariprazine (odds ratio (OR): 2.08, P < 0.01) and for high-dose aripiprazole (OR: 3.00; P = 0.05), but not for low-dose aripiprazole. In bipolar depression, no improvement of remission and response rates was found for aripiprazole in monotherapy, whereas improved response rate (OR: 10.27, P < 0.01) was found for pramipexole only as an add-on to another mood stabilizer. In major depressive disorder, relatively similar improvements of remission rates were found for high-dose (OR: 1.96, p < 0.01) and low-dose aripiprazole (OR: 1.68, P = 0.01), as well as brexpiprazole (OR: 1.52, P = 0.05) as an add-on to antidepressant medication. Our meta-analysis shows that partial dopamine agonists at high doses are effective in treating acute mania. In major depressive disorder, which is resistant to classical antidepressants, low doses of partial dopamine agonists as adjunct therapy may represent a relatively safe and effective alternative.

scholarly journals Efficacy and safety of escitalopram and agomelatine in the treatment of major depressive disorder-A meta-analysis

2021 ◽  
Author(s):  
Yuji Zhan ◽  
◽  
Mengxin Rui ◽  
Wenfeng Zeng ◽  
Yunxia Wang
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
English Language ◽  
Antidepressant Treatment ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Efficacy And Safety ◽  
Major Depressive ◽  
Time Restrictions

Review question / Objective: The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of escitalopram and agomelatine in the major depressive disorder. Condition being studied: Major depressive disorder (MDD), is one of the most common, costly, and disabling mental health conditions worldwide, with an estimated 246 million sufferers globally in 2020.At present, there is a great demand for effective antidepressant treatment in medicine. Information sources: We will search, with no time restrictions, the following databases for relevant English language literature: PubMed, the Cochrane Central Register of Controlled Trials and Web of Science. The search string will be built as follows: (escitalopram) AND (agomelatine) AND (major depressed disorder).

Sign in / Sign up

Export Citation Format

Share Document